- Trials with a EudraCT protocol (186)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
186 result(s) found for: Expanded Disability Status Scale.
Displaying page 1 of 10.
EudraCT Number: 2012-003056-36 | Sponsor Protocol Number: CBAF312A2304 | Start Date*: 2012-10-31 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary pro... | |||||||||||||
Medical condition: Secondary progressive multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Ongoing) IE (Completed) DE (Prematurely Ended) CZ (Completed) SK (Completed) NL (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) AT (Completed) SE (Completed) PT (Prematurely Ended) IT (Prematurely Ended) LV (Completed) GR (Completed) LT (Ongoing) EE (Completed) BE (Prematurely Ended) PL (Completed) BG (Prematurely Ended) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020338-25 | Sponsor Protocol Number: WA25046 | Start Date*: 2010-11-02 | |||||||||||
Sponsor Name:F.Hoffmann-La Roche | |||||||||||||
Full Title: A Phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis | |||||||||||||
Medical condition: Primary Progressive Multiple Sclerosis (PPMS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) ES (Ongoing) BE (Completed) FR (Completed) HU (Completed) NL (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) DE (Completed) PT (Completed) AT (Completed) FI (Completed) IT (Ongoing) GR (Completed) BG (Completed) DK (Prematurely Ended) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000645-14 | Sponsor Protocol Number: EFC16035 | Start Date*: 2020-10-13 | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS) | |||||||||||||
Medical condition: Primary Progressive Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) BG (Ongoing) EE (Ongoing) GB (GB - no longer in EU/EEA) DK (Ongoing) NO (Temporarily Halted) CZ (Ongoing) GR (Ongoing) LV (Ongoing) DE (Restarted) BE (Ongoing) HU (Ongoing) NL (Restarted) PT (Ongoing) IT (Ongoing) HR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000647-30 | Sponsor Protocol Number: EFC16645 | Start Date*: 2020-08-27 | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis | |||||||||||||
Medical condition: Non-relapsing Secondary Progressive Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Ongoing) DE (Restarted) GB (GB - no longer in EU/EEA) CZ (Ongoing) NO (Temporarily Halted) FI (Ongoing) DK (Ongoing) BE (Ongoing) LT (Ongoing) GR (Ongoing) NL (Restarted) PT (Ongoing) PL (Ongoing) HU (Ongoing) IT (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003147-29 | Sponsor Protocol Number: ACT-01_P2_01 | Start Date*: 2020-11-06 |
Sponsor Name:ACCURE TX FRANCE SASU | ||
Full Title: A two-arm randomized double-blind placebo-controlled monocentric study to evaluate the safety and tolerability of ACT-01 compared to placebo in patients with acute optic neuritis | ||
Medical condition: Subjects from 18 to 60 years old with a diagnosis of a unilateral Acute Optic Neuritis with a demyelinating origin, whose symptoms have appeared in the last 10 days before randomization and whose e... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003328-56 | Sponsor Protocol Number: CTU/2014/107 | Start Date*: 2017-12-19 | |||||||||||
Sponsor Name:University College London Comprehensive Clinical Trials Unit | |||||||||||||
Full Title: A phase 3 randomised, double blind, clinical trial investigating the effectiveness of repurposed simvastatin compared to placebo, in secondary progressive multiple sclerosis, in slowing the progres... | |||||||||||||
Medical condition: Multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005418-31 | Sponsor Protocol Number: COMB157G2301 | Start Date*: 2016-10-17 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis | |||||||||||||
Medical condition: multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) HU (Completed) GB (Completed) SE (Completed) DK (Completed) CZ (Completed) SK (Completed) ES (Completed) NL (Completed) EE (Completed) BG (Completed) GR (Completed) PL (Completed) HR (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004703-51 | Sponsor Protocol Number: COMB157G2399 | Start Date*: 2019-01-10 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis | |||||||||||||
Medical condition: Multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) SK (Ongoing) HU (Ongoing) GB (GB - no longer in EU/EEA) NL (Ongoing) AT (Ongoing) FR (Ongoing) PT (Ongoing) ES (Ongoing) CZ (Ongoing) SE (Ongoing) LT (Ongoing) DK (Ongoing) FI (Ongoing) BE (Ongoing) LV (Ongoing) GR (Ongoing) HR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000345-31 | Sponsor Protocol Number: NL56584.092.16 | Start Date*: 2016-09-30 | |||||||||||
Sponsor Name:VU medical center | |||||||||||||
Full Title: Towards personalized dosing of natalizumab in multiple sclerosis | |||||||||||||
Medical condition: multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-015319-41 | Sponsor Protocol Number: TSO-MS | Start Date*: 2011-11-03 |
Sponsor Name:Charite Universitätsmedizin Berlin | ||
Full Title: Trichuris suis Oozyten (TSO®) in remittent-recurrent Multiple Sclerosis (MS) and Clinically Isolated Syndrom (CIS) | ||
Medical condition: remittent-recurrent Multiple Sclerosis (MS) and Clinically Isolated Syndrom (CIS) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2015-005419-33 | Sponsor Protocol Number: COMB157G2302 | Start Date*: 2016-10-21 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis | |||||||||||||
Medical condition: multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) BE (Completed) FI (Completed) GB (Completed) AT (Completed) CZ (Completed) PT (Completed) SK (Completed) ES (Completed) LV (Completed) LT (Completed) BG (Completed) FR (Completed) HR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000644-55 | Sponsor Protocol Number: EFC16034 | Start Date*: 2020-12-22 | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis | |||||||||||||
Medical condition: Relapsing Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) DE (Ongoing) GB (GB - no longer in EU/EEA) CZ (Ongoing) LV (Ongoing) SK (Ongoing) BE (Ongoing) NO (Completed) GR (Ongoing) NL (Ongoing) PT (Ongoing) HU (Ongoing) HR (Ongoing) IT (Ongoing) EE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004980-36 | Sponsor Protocol Number: MS200527-0082 | Start Date*: 2020-09-21 | ||||||||||||||||
Sponsor Name:Merck Healthcare KGaA | ||||||||||||||||||
Full Title: A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Scleros... | ||||||||||||||||||
Medical condition: Relapsing Multiple Sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: PT (Ongoing) LT (Completed) SK (Completed) LV (Ongoing) GR (Ongoing) BG (Ongoing) PL (Ongoing) NO (Prematurely Ended) DE (Prematurely Ended) SI (Completed) IT (Ongoing) RO (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000637-41 | Sponsor Protocol Number: EFC16033 | Start Date*: 2020-07-31 | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis | |||||||||||||
Medical condition: Relapsing Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) BG (Ongoing) CZ (Ongoing) FI (Ongoing) SE (Ongoing) AT (Ongoing) DK (Ongoing) LT (Ongoing) PL (Ongoing) IT (Completed) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002385-32 | Sponsor Protocol Number: APHP211057 | Start Date*: 2022-08-31 |
Sponsor Name:Assistance Publique – Hôpitaux de Paris (AP-HP) | ||
Full Title: Immediate versus delayed treatment with azathioprine or rituximab in anti-myelin oligodendrocytes glycoprotein (anti-MOG) antibodies associated acute demyelinating syndromes in children: a randomiz... | ||
Medical condition: myelin oligodendrocytes glycoprotein antibody associated diseases (MOGAD) | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002937-31 | Sponsor Protocol Number: MA30143 | Start Date*: 2017-09-12 | ||||||||||||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||||||||||||
Full Title: An Open-Label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis | ||||||||||||||||||||||||||||
Medical condition: Relapsing remitting multiple sclerosis (RRMS) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NO (Completed) SE (Completed) AT (Completed) DK (Completed) DE (Completed) PT (Completed) BE (Completed) HU (Completed) PL (Completed) SK (Completed) ES (Ongoing) BG (Completed) SI (Completed) NL (Completed) GB (GB - no longer in EU/EEA) FR (Ongoing) HR (Completed) IT (Ongoing) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-021978-11 | Sponsor Protocol Number: 101MS326 | Start Date*: 2011-05-04 | |||||||||||
Sponsor Name:Biogen Idec Limited | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis | |||||||||||||
Medical condition: Secondary Progressive Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) FI (Completed) CZ (Prematurely Ended) DK (Prematurely Ended) BE (Prematurely Ended) ES (Completed) PL (Prematurely Ended) IT (Prematurely Ended) IE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011516-37 | Sponsor Protocol Number: 14022009 | Start Date*: 2009-05-29 | |||||||||||
Sponsor Name:Danish Multiple Sclerosis Research Centre | |||||||||||||
Full Title: Double blind, placebo-controlled study to assess the effects of Erythropoietin on clinical disability and brain pathology as shown by magnetic resonance imaging in patients with progressive multipl... | |||||||||||||
Medical condition: Multiple Sclerosis, with primary and secondary progressive courses. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-004903-39 | Sponsor Protocol Number: WCNNMBJR001 | Start Date*: 2005-07-26 |
Sponsor Name:The Walton Centre for Neurology and Neurosurgery | ||
Full Title: A pilot multi-centre randomised controlled trial of sequential treatment with Mitoxantrone and Glatiramer Acetate vs. Interferon Beta-1a in early active relapsing remitting Multiple Sclerosis. | ||
Medical condition: Early, active relapsing remitting Multiple Sclerosis (RRMS) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-023172-12 | Sponsor Protocol Number: EFC6058 | Start Date*: 2011-02-15 | |||||||||||
Sponsor Name:sanofi-aventis recherche et development | |||||||||||||
Full Title: A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta. | |||||||||||||
Medical condition: Multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) HU (Completed) BE (Prematurely Ended) SE (Completed) EE (Completed) GB (Prematurely Ended) SK (Completed) ES (Prematurely Ended) NO (Prematurely Ended) DE (Prematurely Ended) FI (Prematurely Ended) GR (Prematurely Ended) PT (Prematurely Ended) IT (Prematurely Ended) AT (Prematurely Ended) DK (Prematurely Ended) LT (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.